Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Instituto Valenciano de Infertilidad, Spain |
---|---|
Information provided by: | Instituto Valenciano de Infertilidad, Spain |
ClinicalTrials.gov Identifier: | NCT00785993 |
Egg-banking would considerably simplify the logistics and means by which oocytes could be donated. These banks would make it easier to immediately provide oocytes that would be compatible to the recipient, shortening or even eliminating the problem of long waiting lists. Egg-banking would also allow the oocytes to be effectively quarantined, drastically diminishing the risk of transmission of infectious diseases in a fashion analogous to semen banks. The most essential prerequisite for a successful egg cryo-banking program is to have an efficient oocyte cryopreservation technology. Recent studies, including our own experience, have indicated that vitrified oocytes preserve intact their potential to fertilize and further develop into competent embryos, giving high clinical results as well as high survival rates. The aim of this study is to evaluate impact of the establishment of an egg-banking in our ovum donation program. Oocyte cryopreservation is carried out by Cryotop method. The study includes oocyte donation cycles conducted with fresh and vitrified oocytes. Recipients are allocated randomly into each group ("fresh vs. vitrified cycles"). Main outcome measures include survival, fertilization, embryo development and clinical outcome.
Condition | Intervention | Phase |
---|---|---|
Egg Banking |
Other: Vitrification of oocytes for IVF treatment Other: Protocolary IVF treatment with fresh donor oocytes |
Phase IV |
Study Type: | Interventional |
Study Design: | Health Services Research, Randomized, Open Label, Active Control, Parallel Assignment, Bio-equivalence Study |
Official Title: | Impact of Egg-Banking in an Ovum-Donation Program |
Estimated Enrollment: | 320 |
Study Start Date: | November 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Control Group: Active Comparator
Fresh donor oocytes
|
Other: Protocolary IVF treatment with fresh donor oocytes |
Group I: Experimental
vitrified donor oocytes
|
Other: Vitrification of oocytes for IVF treatment |
Ages Eligible for Study: | 18 Years to 35 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Receptors
Donors:
Inclusion Criteria:
18 - 35 years oldaños.
Exclusion Criteria:
Contact: Ana Cobo, PhD | 34 96 3050900 | acobo@ivi.es |
Contact: Leslie Atkinson, Ma | 34 963050900 | latkinson@ivi.es |
Spain | |
Instituto Valenciano de Infertilidad | |
Valencia, Spain, 46015 |
Principal Investigator: | Ana Cobo, PhD | Instituto Valenciano de Infertilidad |
Responsible Party: | Instituto Valenciano de Infertilidad, Spain ( Dr. Ana Cobo ) |
Study ID Numbers: | 0703-C-017-AC |
Study First Received: | November 4, 2008 |
Last Updated: | November 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00785993 |
Health Authority: | Spain: Ministry of Health |
Egg banking, clinical outcome |